3 news items
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
RVMD
8 May 24
and PDAC. Objective responses have been observed in second and later line monotherapy treatment of patients with a range of solid tumor types
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
ACB
ACORQ
ADIL
10 Apr 24
. (NASDAQ:KA) dipped 14% to $0.3699. Kineta recently reported initial clinical response data at the AACR 2024 of its ongoing Phase 1/2 VISTA
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
9 Apr 24
/pharmacodynamics modeling, which predicted that daily doses of 100 mg and 300 mg would achieve tumor control and objective responses, respectively
- Prev
- 1
- Next